Selling a Physician Practice: Options, Terms and Trade-offs
You can sell to five types of buyer: a hospital system, a private equity platform, a family office, an insurer or your own partners. Rank their offers on four numbers, not the headline price. Those are cash at close, dollars left at risk in rollover, earnout and escrow, what you keep after tax, and the post-close salary that sets the price in the first place. Size drives the multiple more than anything else you control. In dermatology, FOCUS Investment Banking's 2026 benchmarks put solo practices under $2 million of revenue at 3x to 5x EBITDA and large platforms at 12x to 15x. Structure decides how much of that multiple reaches your account.
Data as of November 20, 2026. Each figure names its source and period. Worked examples are hypothetical, their inputs are stated assumptions and the arithmetic is ours.
Why Physicians Sell, and How to Test Each Bidder Against Your Reason
The AMA's Physician Practice Characteristics in 2024, drawn from its 2024 Physician Practice Benchmark Survey, asked physicians about their reasons for selling. The reason most often rated very important or important was the need to better negotiate higher payment rates with payers (70.8%). Next came improving access to costly resources (64.9%) and better managing payers' regulatory and administrative requirements (63.6%). These are stated motives. The survey does not measure whether selling solved them.
Chart data
| Private practice (physician-owned) | 42.2 |
|---|---|
| Hospital-owned practice | 34.5 |
| Directly employed by hospital | 12.2 |
| Private equity-owned practice | 6.5 |
Source: American Medical Association, Physician Practice Benchmark Survey 2024
| Your reason (AMA 2024 share) | What to ask the buyer | Red flag |
|---|---|---|
| Payer rates (70.8%) | Will rates improve through a stronger contract, an existing network agreement or a billing change, and when? | A vague answer, or one that depends on a single payer |
| Costly resources (64.9%) | What capital for equipment, technology or staff is committed, in what amount and by what date? | Commitments that appear in the pitch deck but not the deal documents |
| Administrative burden (63.6%) | Which functions move to the buyer, and what will your practice pay for them afterward? | Management fees that grow faster than the relief |
If administration is your main problem, price outsourced billing or a services contract before you price a sale. It fixes the same problem without giving up control, and buyers rarely raise it.
5 Buyer Types Compared
| Buyer type | What you give up | What you keep | Typical structure | Main trade-off |
|---|---|---|---|---|
| Hospital or health system | Ownership, billing, most control over staffing, scheduling and the name | Salaried employment or a services agreement, benefits, relief from overhead | Asset purchase plus employment or professional services agreement | Steady pay, limited upside, less say in operations |
| Private equity platform | Control of the business side through an MSO | Clinical control in a physician-owned entity in many structures, rollover equity | Cash at close plus rollover, often with an earnout, escrow and a reset pay formula | Higher potential total value, part of it tied to the platform's later sale |
| Family office | Ownership, sometimes in stages | Local identity in many deals | Direct purchase of a majority or minority stake | Fewer bidders, less standard terms |
| Insurer | Ownership and some independence from that payer's network decisions | Employment in a payer-owned group | Acquisition into a payer-owned provider group | Alignment with one payer changes your position with the others |
| Partner buyout | Some or all of the departing owner's equity | Physician ownership and control for those who stay | Internal buyout funded by partners, practice cash flow or a bank loan, paid in installments | Independence kept, but payment comes over time and depends on former partners |
Which Buyer Fits Which Seller
| Your situation | Approach first | What decides the deal |
|---|---|---|
| Solo owner, two to five years from retirement | Associate or partner buyout, local hospital, family office | Transition length and how much of the price is deferred |
| Mid-career owner of a multi-site group with ancillaries | PE platform, with a hospital as the competing bid | Rollover terms and post-close pay |
| Single site a platform would treat as an add-on | Platforms already in your market, family office | Whether you get add-on pricing with platform-level rollover terms |
| Hospital-based group (emergency, anesthesia, hospitalist) | Sponsors and MSOs active in the specialty, the hospital itself | Term and termination rights of the hospital contract |
| Group that wants to stay physician-run | Minority investor, family office, internal recapitalization | Governance rights and who controls a later sale |
Hospitals and health systems. Most of the value arrives as salary over the employment term, not as a check at closing. Hospitals commission fair market value opinions to support both the purchase price and your pay. Those opinions shape the range the hospital is prepared to defend, which in practice limits how far it will negotiate. The valuation's assumption about your post-close pay feeds straight into the price, so ask to see it.
Systems are also busy buying each other. Becker's Hospital Review, reporting Kaufman Hall data, counts 56 announced hospital and health system transactions in the first three quarters of 2026 (22 in Q1, 18 in Q2, 16 in Q3), against 46 in all of 2025, the lowest annual count since Kaufman Hall began tracking in 2011. Kaufman Hall's Q3 2026 release (October 13, 2026) reports $8.2 billion of transacted revenue in those 16 Q3 deals and an average seller size approaching $586 million of annual revenue. These are system-level deals, not practice acquisitions. They matter to you because a system mid-merger may reset physician pay models, service lines and capital plans after it closes. Ask any hospital bidder whether it is party to a pending transaction.
Hospital-based groups live or die on the hospital contract. In Oregon, PeaceHealth replaced its long-standing emergency department group, Eugene Emergency Physicians, with Lane Emergency Physicians, a practice solely owned by an Illinois physician affiliated with ApolloMD, a Georgia-based MSO (Georgetown CHIR). A buyer prices the term and termination rights of that contract before anything else. Antitrust enforcers watch this segment too. A recent FTC consent order involving a sponsor in this segment includes ongoing reporting on physician practice holdings. Ask your attorney whether any such order affects a bidder.
Private equity platforms buy the business side through a management services organization (MSO), with clinical ownership often left in a physician-owned professional entity. Our guide to private equity physician roll-ups covers platform economics.
Sponsor appetite has cooled but not gone. Bain's Global Healthcare Private Equity Report 2026 finds physician groups fell from 28% of global provider deals in 2021 to 23% in 2025, yet remain "a major part of many private equity (PE) portfolios." Bain also finds the playbook has widened beyond buy-and-build to operational efficiency, including AI and analytics. Ask which of those levers the sponsor will pull in your practice, because each one changes staffing, billing or workflow after closing. Outside the US the sponsor pool is thinner. Bain calls scale physician group investment far less common in Europe and an uncommon theme in Asia-Pacific, where provider deals center on health systems.
Sponsors pay most for a business that can anchor further acquisitions, and add-ons dominate volume. Becker's ASC Review, reporting Private Equity Stakeholder Project (PESP) data, counts 148 deals involving US outpatient care providers in 2025, of which 119 were add-ons (80.4%, our arithmetic). Dermatology led with 24 deals, eye care had 22 and oncology 9. Ask every PE bidder whether you are a platform or an add-on. The answer sets your multiple, your role and your rollover terms.
Family offices often do not behave like PE funds. Many invest their own capital with no fund term that forces a sale. Others have return targets, liquidity needs or succession events that set a timeline, so ask. For a solo practice, a family office willing to price key-person risk instead of refusing the deal may offer the cleanest exit. That risk shows up as a lower price, a longer transition or more deferred payment, so get each in writing. For a larger group, ask whether the family office is buying alone or with co-investors, and who controls the board after closing.
Insurers buy practices into payer-owned groups. Model what happens to your other payer contracts once you sit inside one payer's group.
Partner buyouts keep the practice physician-owned, but your buyers are colleagues and the price comes out of the practice's future cash flow. Bank debt often funds the gap. The SBA 7(a) program, the SBA's main small business loan program, sets a maximum loan amount that can change, so confirm the current limit with your lender. It may not cover a buyout of a large group.
Why Buyers Still Want Practices
The spending base keeps growing. The CMS National Health Expenditure fact sheet reports that physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and CMS projects it will grow 5.5% a year on average from 2025 to 2034. Medicare, which CMS projects as the fastest-growing payer at 7.7% a year over the same period, accounted for 21% of 2024 national health spending. If your practice is Medicare-heavy, expect buyers to model both that growth and the payment-rate risk that comes with it.
3x to 15x: What FOCUS's 2026 Dermatology Benchmarks Show About Size
No public source publishes consistent 2026 multiples across specialties. The most detailed public benchmark is FOCUS Investment Banking's 2026 dermatology valuation guide. These are dermatology ranges. They show how hard size moves the multiple. They are not prices for cardiology, orthopedics or primary care.
| Dermatology practice (FOCUS, 2026) | Size | EBITDA multiple | What the buyer is paying for |
|---|---|---|---|
| Solo practice | Under $2M revenue | 3x to 5x | Owner-dependent, limited reach, physician-to-physician deals |
| Small group | $2M to $15M revenue | 4x to 7x | Broader provider base, medical and cosmetic mix, growing buyer pool |
| Regional or mid-sized platform | $15M to $50M revenue | 8x to 10x | Centralized management, in-house pathology or Mohs, diversified payers |
| Large integrated platform | $50M+ revenue or $10M+ EBITDA | 12x to 15x | Institutional infrastructure, multi-state presence, scalable growth |
The top of the platform band (15x) is three times the top of the solo band (5x). That gap is the sponsor's business model: buy EBITDA at add-on multiples and sell it at platform multiples. Your rollover terms decide how much of the gap you share.
The FOCUS tier descriptions name drivers that carry across specialties. Place your practice on them before you look at any range:
| Driver | Pushes the multiple up | Pushes it down |
|---|---|---|
| Owner dependence | Several producing physicians, associates under contract | One physician generates most collections |
| Ancillaries | In-house imaging, lab, pathology or procedures | Referral-out model |
| Payer mix | Diversified commercial contracts | Concentration in one payer |
| Management | Centralized billing, reporting and leadership | Owner runs operations personally |
| Footprint | Multi-site, dense market presence | Single site |
| Specialty activity | Active consolidation (dermatology and eye care led PESP's 2025 outpatient counts) | Few platforms in the specialty |
Our healthcare valuation multiples guide covers other sectors. Four things separate a published multiple from your cash: the buyer's EBITDA definition, your size and mix, the bridge from enterprise value to equity (debt payoff, working capital, fees) and structure (rollover, earnout, escrow, seller notes).
Example: the salary trade (hypothetical, our arithmetic). A practice earns $2,000,000 a year before interest, taxes, depreciation, amortization and physician compensation. Assume a 5x multiple, an input for the arithmetic, not a benchmark.
| Post-close physician pay | Adjusted EBITDA | Enterprise value at 5x |
|---|---|---|
| $1,400,000 | $600,000 | $3,000,000 |
| $1,200,000 | $800,000 | $4,000,000 |
| Difference: $200,000 a year less pay | +$200,000 | +$1,000,000 |
On a five-year employment agreement you give up $1,000,000 of salary ($200,000 times 5) to gain $1,000,000 of enterprise value. Pre-tax and undiscounted, the trade breaks even.
The simplified rule: before tax and discounting, a pay cut adds value when the multiple exceeds the years the cut lasts. Three adjustments move the answer. Salary arrives over time while the price arrives earlier, which favors the price. Part of the price comes as rollover, earnout or escrow, which carries risk the salary does not. And sale proceeds are often taxed at capital gain rates while wages are ordinary income. Run both sides after tax and at a discount rate that reflects the risk. Test your numbers in the practice valuation calculator.
Higher Multiple, Less Cash: Comparing Two Offers
Example: two offers for the same dermatology group (hypothetical, our arithmetic). Adjusted EBITDA is $1,200,000. Both multiples sit inside FOCUS's 4x to 7x 2026 small-group band. The 10% escrow on headline price, the 20% rollover and the earnout are assumptions. The earnout counts inside the headline price.
| Line item | Offer A: 5.5x, mostly cash | Offer B: 6.5x, structured |
|---|---|---|
| Headline price | $6,600,000 | $7,800,000 |
| Rollover equity (20% of headline in B) | $0 | $1,560,000 |
| Earnout, paid in year 2 if targets are met | $0 | $1,000,000 |
| Escrow (10% of headline) | $660,000 | $780,000 |
| Cash at close | $5,940,000 | $4,460,000 |
Assume escrow is released in full, undiscounted. Assume a 60% chance the earnout pays, discounted at 10% a year for two years: $1,000,000 times 0.60, divided by 1.21, is about $495,900. Offer A is worth $6,600,000. Offer B before rollover is worth $4,460,000 plus $780,000 plus $495,900, or about $5,735,900.
Offer B wins only if the rollover is worth more than the gap of about $864,100, which is about 55% of its $1,560,000 entry value. Pre-tax, before fees.
The higher multiple is a bet that the rollover holds more than half its value and the earnout pays. If you would not make that bet with $864,100 of your own cash, take the lower multiple.
Seller financing lends part of your price back to the buyer, usually for a higher headline. Get the rate, term, payment schedule, ranking against bank debt and any guarantee in writing. If the practice struggles, the note is the part of your price at risk.
Offer Scorecard
Bidders format offers differently on purpose. Put every bid on one page.
| Line | Record for each offer |
|---|---|
| Headline price and multiple | And the adjusted EBITDA the buyer used |
| Post-close pay | Base, productivity formula, term, EBITDA effect |
| Cash at close | After rollover, earnout, escrow, seller note, debt payoff and fees |
| After-tax proceeds | Asset or equity deal, price allocation, rollover deferral |
| Rollover | Amount, entry valuation, security class, platform debt |
| Earnout | Metric, period, covenants, probability-weighted value |
| Escrow and RWI | Percentage, base, survival period, your share of the premium |
| Post-close restrictions | Non-compete scope, name rights, termination effects |
| Certainty | Financing source, remaining diligence, approvals needed before closing |
Keeping the Building
Published multiples price the practice, not the property. An owner who keeps the building negotiates a lease alongside the sale.
Example: the rent trade (hypothetical, our arithmetic). Rent above what is already in your earnings comes off adjusted EBITDA. At the same assumed 5x, an extra $50,000 of annual rent cuts enterprise value by $250,000 while paying you $50,000 a year. A ten-year lease returns $500,000, undiscounted and before tax.
Higher rent wins, on the same simplified pre-tax rule, when the lease term exceeds the multiple. A buyer you refer patients to will expect rent at fair market value, so get an independent rent appraisal and settle term, renewals and any purchase option before the LOI.
After Tax: Structure Decides What You Keep
Two offers at the same price can leave you with very different after-tax cash. Settle structure and price allocation before the LOI, because buyers rarely reopen them afterward.
| Structure choice | Buyer's preference | Seller's preference | Medicare billing after closing |
|---|---|---|---|
| Asset purchase | Usually preferred: step-up in asset tax basis, leaves most pre-closing liabilities with you | Part of the price can be taxed as ordinary income, and a C corporation seller can face two layers of tax | Buyer bills under its own enrollment, and physicians reassign billing to it. Collections can lag |
| Equity purchase | Takes on the entity's history, so it asks for broader indemnities | Gain is more often capital gain at the owner level | The entity, its enrollment and tax ID can stay in place, with the ownership change reported to Medicare |
Three tax levers matter most in practice sales:
- Price allocation. In an asset deal, the price is split among equipment, receivables, goodwill and any non-compete. Goodwill is usually taxed as capital gain to the seller. Payments for a non-compete are ordinary income. Depreciated equipment can trigger ordinary income on recapture.
- Personal goodwill. Where patient relationships belong to the physician rather than the entity, part of the price can be paid for the physician's personal goodwill directly. For a C corporation practice this can avoid the corporate tax layer. It needs valuation support and facts that hold up, such as no existing non-compete between you and your own entity.
- Rollover deferral. A properly structured rollover lets you defer tax on the rolled portion until the platform sells. You still owe tax on the cash, so check that the cash covers the bill.
Example: allocation of $1,000,000 (hypothetical, our arithmetic). Assume a 20% federal rate on capital gain and a 37% rate on ordinary income, ignoring state tax, the net investment income tax and basis. Allocated to goodwill, $1,000,000 nets $800,000. Allocated to a non-compete, it nets $630,000. Same price, $170,000 apart.
Rollover Equity and the Second Bite
Rollover means reinvesting part of your price in the buyer's platform instead of taking it in cash. You get a second payment if the platform later sells at a higher value. It is an equity bet on a business you no longer control, and buyers like it because it keeps you working toward their exit. Check whether your units keep their value if you stop working. That tells you whether the rollover is an investment or a retention tool.
The second bite depends on a platform exit. Bain's 2026 report describes Cardinal Health's original acquisition of GI Alliance "from a group of physician owners and Apollo Global Management." That is the exit a rollover holder is waiting for: a strategic buyer purchasing a sponsor-backed platform, with physician owners selling alongside the sponsor.
| Term | What to get in writing | Why it moves your payout |
|---|---|---|
| Entry valuation | The valuation at which your units are issued | Rolling in at your practice's multiple buys more of the business than rolling in at a platform multiple |
| Security class | Common or preferred, and any liquidation preference ahead of you | Common is paid after preferred |
| Platform debt | Debt-to-EBITDA and maturities, now and at the credit agreement's limit | Lenders are repaid before any equity |
| Dilution | Protection when the platform issues equity to fund acquisitions | New issuance shrinks your share |
| Exit control | Drag-along, tag-along and information rights | Drag-along lets the sponsor sell on its timetable |
| Leaving early | Repurchase rights, price and vesting on departure or termination | Some agreements allow buybacks below market value |
Example: where the rollover is priced (hypothetical, our arithmetic). A dermatology group has $8,000,000 of revenue and $1,200,000 of adjusted EBITDA (15% margin), inside FOCUS's 2026 small-group band. It sells at an assumed 6x for $7,200,000 and rolls 20%, or $1,440,000. Assume no platform debt, no preferred equity, no dilution, no fees and no EBITDA growth, to isolate entry price.
| Rollover priced at | EBITDA your $1,440,000 claims | Value if the platform sells at 12x |
|---|---|---|
| Your 6x | $240,000 ($1,440,000 ÷ 6) | $2,880,000 ($240,000 × 12) |
| A 12x platform valuation | $120,000 ($1,440,000 ÷ 12) | $1,440,000 ($120,000 × 12) |
At the platform valuation, the same dollars buy half the claim, and a 12x exit only returns your money.
Real platforms carry acquisition debt and often preferred equity, both paid ahead of your common units, and later raises dilute you. Each reduces the figures above. Ask for the cap table and full waterfall, and check how often and how much the platform has raised by searching its Form D notices on SEC EDGAR full-text search. Ask for platform margins with every acquired physician on salary, not pre-acquisition earnings. A roll-up that works only on pre-acquisition numbers leaves rollover worth less than the cash you traded for it. Model scenarios in the rollover equity calculator and work through the physician rollover equity checklist.
Earnouts: Contingent Money You Negotiate Up Front
An earnout pays part of the price only if the practice hits targets after closing. Value it below face, as the two-offer example does, and settle these terms at the LOI:
- Metric. Revenue or collections over EBITDA. If EBITDA is used, cap the corporate overhead charged to your practice.
- Period. Shorter leaves less time for changes you do not control.
- Operating covenants. Commit the buyer to the staffing, payer contracts, locations and scheduling the targets assume.
- Access and disputes. The right to see the numbers, and an independent accountant to resolve disputes by a set deadline.
- Acceleration. Full payout if the platform is sold or you are terminated without cause.
- Set-off. Limit deductions of indemnity claims from earnout payments, so one claim cannot freeze both escrow and earnout.
- Referral neutrality. If you will keep referring to the buyer, tie the earnout to measures that do not rise with your referrals.
| Earnout design | Who controls the outcome | How to value it |
|---|---|---|
| Revenue or collections target | Mostly you and your providers | Closest to face if covenants protect staffing |
| EBITDA target | Shared, since the buyer sets overhead and pay | Discount heavily unless allocations are capped |
| Milestone (new site, service line) | Mostly the buyer's capital decisions | Treat as upside, not price |
Price any earnout in the earnout value calculator.
Escrow and RWI: Day-One Cash Versus Recoverable Cash
Escrow is the part of the price held back to cover breaches of your representations and warranties. Representations and warranties insurance (RWI) moves part of that risk to an insurer, so buyers accept a smaller holdback. It does not move all of it. A policy pays only above its retention and up to its limit, excludes issues known or found in diligence, and underwriters in healthcare deals often exclude or narrow coverage for billing and coding. Losses outside the policy come back to the escrow, a special indemnity or you.
Example (hypothetical, our arithmetic). A $10,000,000 headline price that counts the earnout at full value, with 20% rolled ($2,000,000) and a $1,000,000 earnout. Assumed rates: 10% escrow without RWI, 1% with RWI, and a $300,000 premium split evenly. Escrow applies to the full headline.
| Line item | A: no RWI | B: with RWI |
|---|---|---|
| Headline price | $10,000,000 | $10,000,000 |
| Less rollover (20%) | $2,000,000 | $2,000,000 |
| Less contingent earnout | $1,000,000 | $1,000,000 |
| Less escrow | $1,000,000 (10%) | $100,000 (1%) |
| Less seller's half of RWI premium | $0 | $150,000 |
| Cash at close | $6,000,000 | $6,750,000 |
| Cash at close as share of headline | 60.0% | 67.5% |
| Total cash if escrow is released in full | $7,000,000 | $6,850,000 |
B puts $750,000 more in your account on day one. If no claims are made, A ends $150,000 ahead, because escrow comes back and a premium does not. If escrow is sized on cash consideration only ($7,000,000 here), A holds back $700,000 and cash at close rises to $6,300,000.
Even in B, $3,250,000 of the $10,000,000 headline is not in your account at closing, before fees, debt payoff and taxes. RWI earns its premium when you need the cash now or your diligence record has open questions. With clean books and patience for the survival period, a larger escrow can cost less. Run your figures in the deal proceeds calculator.
Regulatory Areas That Change Deal Structure
These areas decide what a buyer can own, how it gets paid and how long closing takes. Each is fact-specific, so have your attorney review all of them before you sign the LOI. Our healthcare compliance due diligence guide goes deeper.
| Area | Effect on your deal | Read more |
|---|---|---|
| Medicare enrollment and billing | A billing number cannot be sold. Asset or equity structure decides how billing continues and how long collections lag | CMS |
| Federal referral and self-referral rules | Can affect in-office ancillaries, leases, directorships, and rollover or earnouts held by physicians who refer to the buyer. Ask your attorney how they apply | HHS OIG |
| Corporate practice of medicine | Can limit whether a non-physician buyer can own the practice and how an MSO is built. Some states, including Oregon, have recently tightened these rules (Georgetown CHIR). Ask your attorney how your state's rules apply | Your state medical board |
| State healthcare transaction notice laws | A growing number of states require notice or review before certain practice deals close. Ask your attorney whether your deal is covered | Your state health agency |
| Federal antitrust | Larger deals can require premerger notice, and the FTC scrutinizes specialty roll-ups | FTC |
| Non-competes | Enforceability varies by state, and some states restrict them in physician agreements | Your state's statutes |
What Buyers Test in Diligence
Buyers price compliance gaps as escrow claims, special indemnities or a lower multiple. Fix what you can first.
| Item | What the buyer checks | How it shows up in your deal |
|---|---|---|
| In-office ancillaries | How imaging, lab and pathology referrals are structured | Ancillary revenue supports premium multiples, so any structural doubt moves price |
| Coding and billing | A claims sample against documentation | Overpayments become a price cut or special indemnity |
| Copayment waivers | How and when patient balances are waived | Routine, undocumented waivers become a finding and a likely special indemnity |
| Referral-source arrangements | Leases, directorships and other payments to or from referral sources | Arrangements without written fair-market terms become special indemnities |
| Hospital contracts | Assignment, change-of-control and termination clauses | For hospital-based groups, most of the value |
Before You Go to Market
- Normalize your financials. Strip owner perks and one-time costs, and show EBITDA at a market physician salary. Benchmark staff wages against current BLS health care industry data. Your version anchors the discussion.
- Inventory payer contracts. Rates, term dates and assignment clauses for each.
- Run a compliance self-review. Coding, waivers, and any leases or directorships with referral sources.
- Sign key physicians and staff. Associates without agreements read as key-person risk.
- Clean up ownership. Confirm who owns what, and settle partner disputes and buy-sell terms.
- Separate the real estate. Decide whether the building is in the deal, and appraise the rent if not.
- Model after-tax proceeds. Know your number under an asset and an equity structure before any bidder sets one.
Running the Sale: Six Phases and Where the Price Leaks
In Offer B above, $3,340,000 of the $7,800,000 headline ($7,800,000 less $4,460,000 cash at close) sits in rollover, earnout and escrow before fees, debt payoff or taxes. Most of that gap is set in phases 3 and 5.
| Phase | What happens | What you control | Where value leaks |
|---|---|---|---|
| 1. Preparation | Normalized financials, sell-side quality of earnings, compliance self-review | The adjusted EBITDA you present | Gaps buyers later price as special indemnities |
| 2. Marketing | Buyers contacted under confidentiality agreements | Which buyer types and how many | A single-bidder process removes price tension |
| 3. Indications and LOI | Bidders submit price and structure, you sign one LOI with exclusivity | Every scorecard line, while competing bids exist | Rollover, earnout and escrow left "to be agreed" |
| 4. Confirmatory diligence | Buyer's accountants, coders and counsel test your numbers | Speed and completeness of responses | Re-trades after competing bidders are gone |
| 5. Definitive documents and approvals | Purchase, employment and rollover documents, enrollment steps, any state or federal reviews | Indemnity caps, escrow base, covenants, termination effects | Working capital peg and debt-like items |
| 6. Post-close | Earnout measurement, escrow release, rollover holding period | Access to books and dispute rights | Overhead allocations and set-off |
| Advisor | What they do | Ask before hiring |
|---|---|---|
| Sell-side banker or broker | Builds the buyer list, keeps bidders competing | Recent sales in your specialty and size, fee structure, and registration and disclosure history on FINRA BrokerCheck |
| Transaction attorney | Negotiates the LOI and definitive documents | Sell-side healthcare deal count, not general corporate work |
| Quality of earnings accountant | Makes your adjusted EBITDA hold up in diligence | Add-backs defended in physician practice deals |
| Tax advisor | Models structure, allocation and rollover after tax | Whether they will rank offers after tax |
| Financial planner | Sizes the cash you need against what you can leave at risk | How they are paid |
Bring in the accountant and tax advisor before the first buyer sees a summary. At the assumed 5x in the salary example, every $100,000 of add-backs a buyer rejects removes $500,000 of enterprise value. Our healthcare M&A process guide covers timing, and how to choose a healthcare investment banker covers who can be paid to find buyers.
Before the LOI: Six Questions to Settle
The LOI is where bargaining power shifts, because exclusivity starts and competing bids stop. A buyer will identify the physician who actually brings in patients and referrals, price them as key-person risk and write their retention into the employment terms. Your employment agreement and rights to your name are part of the price.
A promise that nothing will change for patients is a pitch, not a contract term. Have each bidder write continuity promises in as operating covenants on staff, name, locations and scheduling, and list in writing what will change behind the front desk.
Get written answers to these before you sign, then check the draft against our LOI and term sheet red flags:
- What is my post-close pay, and how much enterprise value does it add or remove?
- What is cash at close after rollover, earnout, escrow, seller notes, debt payoff and fees, and what is it after tax?
- Is the deal an asset or equity purchase, and how is the price allocated?
- What security is my rollover, at what valuation, behind how much debt and preferred equity, and what happens to it if I leave?
- What triggers the earnout, and who controls its inputs?
- Is RWI in the deal, what are its retention and exclusions, what base does the escrow use and who pays the premium?
Questions Practice Owners and Investors Ask
Why do physicians sell their practices?
In the AMA's 2024 Physician Practice Benchmark Survey, the reasons physicians most often rated very important or important for selling were better negotiating payment rates with payers (70.8%), improving access to costly resources (64.9%) and better managing payers' regulatory and administrative requirements (63.6%). Ask every bidder how it will deliver on the reason that applies to you, and get the answer into the deal documents.
What EBITDA multiple does a physician practice sell for?
Size sets the bracket. The most detailed public 2026 benchmark covers dermatology only. FOCUS Investment Banking puts solo dermatology practices under $2 million of revenue at 3x to 5x EBITDA and platforms with $50 million or more of revenue or $10 million or more of EBITDA at 12x to 15x. Buyers apply any multiple to their own adjusted EBITDA, after resetting physician pay to a post-close salary.
How should I evaluate an earnout when selling a medical practice?
Value it below face, weighted by the odds it pays and discounted for the wait. Prefer a revenue or collections metric, which the buyer cannot shrink through overhead allocations, and settle the period, operating covenants, access to the books and a dispute process in the LOI.
How much of the sale price is held back in escrow?
Escrow is negotiated, and the base matters as much as the percentage. Ask whether it applies to the full headline price or to cash consideration only. Representations and warranties insurance lets buyers accept a smaller holdback, but the policy has a retention, a limit and exclusions, so some risk stays with you.
Can I sell my Medicare billing number with the practice?
No. Medicare prohibits a provider or supplier from selling its billing number or letting another party use it. In an asset purchase the buyer bills under its own enrollment and your physicians reassign billing to it. In an equity purchase the practice entity, its enrollment and its tax ID can stay in place, with the ownership change reported to Medicare. Either way, build enrollment timing into the closing plan and the working capital terms.
Is a family office a better buyer than private equity for a medical practice?
Neither wins by default. Many family offices invest their own capital with no fund term that forces a sale, and some will price a single-doctor practice that platforms pass on. Others have return targets or liquidity needs that set a timeline. Compare cash at close, employment terms and the treatment of any equity you keep.
Sources
- AMA Policy Research Perspective: Physician Practice Characteristics in 2024, 2024 Physician Practice Benchmark Survey
- CMS National Health Expenditure fact sheet, 2024 data and 2025 to 2034 projections
- FOCUS Investment Banking: Dermatology Practice Valuation, 2026 Benchmarks
- Bain & Company: New Models of Value Creation for Physician Groups, Global Healthcare Private Equity Report 2026
- Becker's ASC Review: The outpatient specialties that dominated 2025 deal activity, reporting PESP 2025 data
- Becker's Hospital Review: Hospital M&A on pace for busiest year since pandemic, reporting Kaufman Hall data through Q3 2026
- Kaufman Hall: Q3 2026 M&A Quarterly Activity Report press release, October 13, 2026
- Georgetown CHIR: Oregon's multi-pronged approach to corporate influence in physician practices
- FTC consent order involving a physician practice roll-up, 2025
- HHS OIG: A Roadmap for New Physicians, Fraud and Abuse Laws
- SBA 7(a) loan program
- SEC EDGAR full-text search
- FINRA BrokerCheck
- U.S. Bureau of Labor Statistics: Health Care and Social Assistance